Indication
Spinocerebellar Ataxia Type 3
6 clinical trials
7 products
1 drug
Product
troriluzoleClinical trial
A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects With Spinocerebellar Ataxia.Status: Active (not recruiting), Estimated PCD: 2022-02-18
Product
PlacebosClinical trial
A Phase 1/2a, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered VO659 in Participants With Spinocerebellar Ataxia Types 1, 3 and Huntington's DiseaseStatus: Recruiting, Estimated PCD: 2025-09-01
Product
VO659Clinical trial
A Clinical Research on the Safety/Efficacy of Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Spinocerebellar AtaxiaStatus: Not yet recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase 1, Blinded, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of BIIB132 Administered Intrathecally to Adults With Spinocerebellar Ataxia 3Status: Terminated, Estimated PCD: 2023-07-25
Product
BIIB132Clinical trial
Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) to Study Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias (SCA)Status: Recruiting, Estimated PCD: 2024-05-19
Product
All ParticipantsClinical trial
A Double-blind, Randomized, Placebo Controlled, Trial to Assess Safety and Efficacy of SLS-005 (Trehalose Injection, 90.5 mg/mL for Intravenous Infusion) for the Treatment of Adults With Spinocerebellar AtaxiaStatus: Terminated, Estimated PCD: 2023-11-24
Product
SLS-005Drug
Varlilumab